Claims

1. Liver sinusoidal endothelial cells (LSECs) or activated LSECs for use in a method of enhancing liver regeneration in a mammal in need thereof, said liver regeneration comprising proliferation of hepatocytes and regeneration of liver mass, and said method comprising intrahepatic transplantation of said LSECs to said mammal, wherein said mammal is in need of proliferation of hepatocytes and regeneration of liver mass.

2. The LSECs or activated LSECs for use according to claims 1, wherein the LSECs or activated LSECs are VEGFR2+VE-cadherin+VEGFR3+CD34- factor VIW Prox1-CD45- LSECs.

3. The LSECs or activated LSECs for use according to claim 1, wherein the LSECs or activated LSECs are VEGFR2+VEGFR3+CD34-ld1 + LSECs which induce hepatic proliferation.

4. The LSECs or activated LSECs for use according to claim 1, wherein the method further comprises administration of hepatocytes.

5. A pharmaceutical composition for use in a method of enhancing liver regeneration in a mammal in need thereof, said liver regeneration comprising proliferation of hepatocytes and regeneration of liver mass, and said pharmaceutical composition comprising LSECs or activated LSECs as recited in anyone of claims 1 to 3 and a pharmaceutically acceptable carrier; wherein said mammal is in need of proliferation of hepatocytes and regeneration of liver mass.